KR20210118492A - A composition for improving memory, cognitive function, or preventing and improving brain neurological diseases - Google Patents

Abstract

The present invention relates to a composition for improving memory, cognitive function, or preventing and alleviating neurological diseases. The composition for improving memory and cognitive function according to an embodiment of the present invention can include an extract of Erigeron annuus. The present invention is the composition for improving memory and cognitive function further containing a Brassica oleracea extract.

Description

Composition for improving memory, cognitive function, or preventing and improving cranial nerve disease {A COMPOSITION FOR IMPROVING MEMORY, COGNITIVE FUNCTION, OR PREVENTING AND IMPROVING BRAIN NEUROLOGICAL DISEASES}

The present invention relates to a composition for improving memory, cognitive function, or preventing and improving cranial nerve disease. More particularly, it relates to a composition for improving memory, cognitive function, or preventing and improving cranial nerve disease, which can exhibit rapid improvement activity at an early stage with excellent initial improvement activity.

The proportion of the elderly population is rapidly increasing worldwide, and according to a recent analysis, the number of people aged 60 and over will reach 2 billion by 2050. As of 2013, according to the data of the National Statistical Office, Korea's aging index (the ratio of the population aged 65 and over to the population under 15) was 83.3%, and the proportion of the population aged 65 and over was 12.2%. As the elderly population increases, geriatric diseases are increasing, and countermeasures are urgently discussed. Among the diseases of the elderly, one of the most problematic is cognitive impairment dementia (dementia). Dementia refers to a continuous and overall decline in cognitive functions such as memory, language ability, temporal and spatial understanding and judgment, and abstract thinking ability due to impaired brain function. Dementia is a type of brain disease and is known to be caused by various causes such as Alzheimer's disease and vascular dementia, as well as degenerative brain diseases such as Parkinson's disease, head trauma, and infectious diseases. Therefore, it can be said that efforts to treat and manage dementia diseases, which are rapidly increasing along with the exponential increase in the elderly population, are urgently needed.

Dementia, a representative chronic degenerative brain disease, is defined as a complex of symptoms that affects both mental cognitive ability and social behavioral ability, leading to disturbances in normal daily life. There are three main types of dementia depending on the cause. Alzheimer's disease (AD), in which cognitive function deteriorates without a clear cause, vascular dementia (VD) caused by cerebrovascular diseases such as repeated cerebral infarction, and other diseases classified as dementia caused by Since the main cause of cerebrovascular dementia is infarction caused by arteriosclerosis, symptoms can be improved by treatment with thrombolytic drugs, etc., but the cause of Alzheimer's disease is still not fully elucidated despite active research by many researchers.

As a result of the research so far, it was found that Alzheimer's disease is pathologically characterized by brain atrophy in the cerebral cortex or hippocampus and the deposition of senile plaques or neurofibrillary tangles in the brain (Selkoe DJ, Alzheimer's). disease: Genes, proteins, and therapy, Physiol. Rev., 81, pp.741-766, 2001). Observing the pathogenesis of Alzheimer's disease, it was found that a protein called β-amyloid (Aβ) was accumulated, followed by the accumulation of neurofibrillary tangles at the same time as dementia appeared. The senile plaque is a sympathetic spot-like structure seen in the cerebral cortex and hippocampus of the brain, with amyloid fibers in the center and degenerated nerve cell projections surrounding it. That is, beta-amyloid is a major component of the senile plaque accumulated in the brain of Alzheimer's disease patients, and its toxicity to nerve cells is thought to be the main cause of Alzheimer's disease (Hardy, JA et al., Alzheimer's disease). disease: The amyloid cascade hypothesis, Science, 256, pp.184-185, 1992).

Although the mechanism of action of excessively produced beta-amyloid causing toxicity is diverse, the disease progression can be largely explained by the following two theories. The first theory is that when amyloid plaques develop, glia become inflamed, triggering a series of inflammatory responses that eventually damage nerves and stimulate the production of attacking cytokines. The second theory is based on the action of reactive oxygen species (ROS). More than 95% of the brain is composed of fat and is oxidized under attack by free radicals. Beta-amyloid undergoes aggregation to form reactive oxygen species such as hydrogen peroxide, superoxide anion, and hydroxylradical, which are large in vivo due to their high reactivity. It affects molecules and ultimately leads to active apoptosis in neurons (Markesbery WR, Oxidative stress hypothesis in Alzheimer's disease, The amyloid cascade hypothesis, Free Radic. Biol. Med., 23, pp.134- 147, 1992).

Memory and cognitive impairment is the first and most common symptom experienced by people with Alzheimer's disease. In the early stages of Alzheimer's disease, patients suffer from a recent memory disorder that prevents them from remembering the details of recent conversations or events. . However, during this period, the remote long-term memory of events in the distant past is relatively well maintained. However, as the disease progresses, the cerebral cortex related to the storage of long-term memories is damaged, and these past memories are also gradually impaired.

On the other hand, if the area where the cerebral artery is blocked by a blood clot that occurs following atherosclerosis and the tissue is killed occurs in an important area such as the hippocampus, it develops into dementia. or subcortical ischemic vascular dementia (SIVD) (35 to 67% of all vascular dementias), which is caused by insufficient blood supply (Roman et al., Subcortical ischemic vascular dementia. Lancet Neurol 2002;1) :426-436). Injury in subcortical ischemic vascular dementia (SIVD) mainly occurs in the white matter, and various methods are used to make animal models resembling these diseases (Hainsworth & Markus, Do in vivo experimental models reflect human cerebral small vessel disease; A systematic review (J Cerebral Blood Flow & Metabolism 2008;28:1877-1891). For vascular dementia, it has been found that oligodendrocytes constituting the white matter die by apoptosis under conditions in which vascular dementia occurs, and research is underway to suppress it and treat it.

KR 10-2015-0107938 A KR 10-2019-0018897 A

An object of the present invention is to provide a composition for improving memory and cognitive function.

It is an object of the present invention to provide a composition for preventing and improving cranial nerve diseases including dementia and Alzheimer's.

It is an object of the present invention to provide a composition that enables rapid improvement in the initial stage with excellent initial activity and does not have a problem of side effects due to long-term administration using a plant-derived natural extract.

An object of the present invention is to provide a food composition that can improve learning ability and concentration.

In order to achieve the above object, the composition for improving memory and cognitive function according to an embodiment of the present invention may include an extract of Ilnyeonbong.

The composition for improving memory and cognitive function may further include a New Green extract.

The composition for preventing and improving cranial nerve disease according to another embodiment of the present invention may include an extract of one year bong.

The composition for preventing and improving cranial nerve disease may further include a New Green extract.

In the composition for preventing and improving cranial nerve disease, the cranial nerve disease is selected from the group consisting of neurodegenerative diseases, diseases and psychiatric disorders caused by ischemia or reperfusion, and the neurodegenerative diseases are Parkinson's disease, Huntington's disease, Alzheimer's disease, mild Cognitive impairment, senile dementia, amyotrophic lateral sclerosis, Spinocerebellar Atrophy, Tourette's Syndrome, Friedrich's Ataxia, Machado-Joseph's disease ( Machado-Joseph's disease), Lewy Body Dementia, Dystonia, Progressive Supranuclear Palsy and Frontotemporal Dementia may be selected from the group consisting of.

A pharmaceutical according to another embodiment of the present invention may include the composition.

Food according to another embodiment of the present invention may include the composition.

Hereinafter, the present invention will be described in more detail.

The composition for improving memory and cognitive function according to an embodiment of the present invention may include an extract of Ilnyeonbong.

The composition for preventing and improving cranial nerve disease according to another embodiment of the present invention may include an extract of one year bong.

Irnyunbong is a biennial herb that has thick hairs and grows upright and grows up to 1 m in height. The inflorescence is about 2 cm in diameter and hangs at the end of the branch in coaxial inflorescences. The edge of the flower cluster is a white tongue flower, which blooms in a single row, and there are several yellow, tube-shaped flowers inside.

A variety of extraction solvents may be used. Preferably, a polar solvent or a non-polar solvent may be used. Suitable as polar solvents are: (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) DMFO (dimethylformamide) and (v) DMSO (dimethyl sulfoxide). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- Pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloro methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride and THF.

More easily, the extraction solvent used in the present invention is (a) water, (b) an anhydrous or hydrated lower alcohol having 1-4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) the lower alcohol and water mixed solvent with, (d) acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether include More easily, the extract of the present invention is obtained by treating water with one year rod.

The amount of the solvent may vary depending on the amount of the annual rod to be extracted, preferably 1 to 20 times the weight of the annual rod (w/v%), more preferably 5 to 10 times the volume (w/v%) ( w/v%).

The extraction temperature of the extract is not particularly limited, and may be, for example, 0°C to 120°C, preferably 50°C to 100°C. Extraction time of the extract of the present invention is not particularly limited, and may be, for example, 1 hour to 10 days, preferably about 3 hours to 7 hours.

The extract of the present invention may be extracted by a known natural product extraction method. For example, extraction may be performed by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, or heating extraction method, preferably by hot water extraction or reflux cooling extraction method, 1 to 10 times, preferably 2 times Extraction can be repeated to 4 times.

In addition, the extract may be filtered and used in a liquid form, preferably, it may be used after being solidified through a drying process of spray drying or freeze-drying. More preferably, it may be dried by mixing dextrin before spray drying or freeze drying.

As used herein, the term "extract" has the meaning commonly used as a crude extract in the art as described above, but in a broad sense also includes a fraction obtained by additionally fractionating the extract. That is, the extract of Ilnyeonbong includes not only those obtained by using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity), etc. The fractions obtained through the purification method are also included in the extract of Ilnyeonbong of the present invention.

In the case of including the Ilnyeonbong extract, it is possible to exhibit the effect of improving cognitive function and memory.

The composition for improving memory and cognitive function may further include a New Green extract.

New green is a genus Brassica native to the coasts of southern and western Europe. Wild newgreens are biennials and have been cultivated for thousands of years. New greens include kale (Brassica oleracea Acephala Group), cayenne (Brassica oleracea Alboglabra Group), cauliflower (cauliflower, brocoflower, Brassica oleracea Botrytis Group), cabbage (red greens, Brassica oleracea Capitata Group), Brussels sprouts, It is divided into seven cultivars: oleracea Gemmifera Group), kohlrabi (Brassica oleracea Gongylodes Group) and broccoli (Brassica oleracea Italica Group).

When the New Green extract is further included, the effect of improving cognitive function and memory may be more excellent.

Preferably, the composition for improving memory and cognitive function may be one in which the New Green extract is mixed in an amount of 10 to 5000 parts by weight based on 100 parts by weight of the Ilnyeonbong extract. According to the above range, the effect of improving memory and cognitive function may be more enhanced according to the mixing of each extract.

More preferably, the composition for improving memory and cognitive function may include 400 to 500 parts by weight of the New Green extract based on 100 parts by weight of the Ilnyeonbong extract. In the case of the above range, it can be confirmed that not only a synergistic effect by interaction appears, but also the initial rapid improvement activity appears unlike the case of using each extract alone. It can be seen that the active substances contained in each extract exhibit a synergistic effect by interaction within the above range, and the effect of improving cognitive function and memory at the initial stage of administration due to rapid activity.

The composition for preventing and improving cranial nerve disease according to another embodiment of the present invention may include an extract of one year bong.

In the case of including the extract of one year bong, it may exhibit a preventive and ameliorating effect on cranial nerve diseases.

The composition for preventing and improving cranial nerve disease may further include a New Green extract.

When the New Green extract is further included, the prevention and improvement effect on cranial nerve diseases can be enhanced.

Preferably, the composition for preventing and improving cranial nerve disease may be one in which the New Green extract is mixed in an amount of 10 to 5000 parts by weight based on 100 parts by weight of the annual extract. When according to the above range, the prevention and improvement effect for cranial nerve diseases may be further improved according to the mixing of each extract.

More preferably, the composition for preventing and improving cranial nerve disease may include 400 to 500 parts by weight of the New Green extract based on 100 parts by weight of the annual extract. In the case of the above range, it can be confirmed that not only a synergistic effect by interaction appears, but also the initial rapid improvement activity appears unlike the case of using each extract alone. It can be seen that the active substances contained in each extract exhibit a synergistic effect by interaction in the above range, and exhibit the effect for preventing and improving the cranial nerve disease at the initial stage of administration due to rapid activity.

More preferably, the composition for improving memory and cognitive function or the composition for preventing and improving cranial nerve disease comprises an extract of ilyeongbong, 400 to 500 parts by weight of New Green extract based on 100 parts by weight of the ilanbong extract; It may include 40 to 80 parts by weight of the milk thistle extract and 1 to 3 parts by weight of the sangoschi extract.

In the case of the above range, the effect of improving memory and cognitive function and the prevention and improvement of cranial nerve disease are greatly improved, and the effect can appear very quickly at the beginning of administration. Therefore, it is possible to exhibit a rapid improvement effect while using a small amount.

The thistle is a perennial herb covered with hairs, branching a little at the top, and growing upright, and a large one reaches about 1 m. The leaves are long oval in shape and have large and small thorns on the edge. Purple or red flowers bloom upwards one at the end of a branch in midsummer. Each flower contains hundreds of small, barrel-shaped flowers, with hairs on the fruit.

The mountain chrysanthemum is a dicotyledonous perennial plant of the Asteraceae family of the order Asteraceae, which grows in a deep mountain, and the stem stands upright and branches out at the upper part. The base of the leaf flows into the stem and becomes the wing of the stem, and the leaf attached to the root and the leaf attached to the lower part fall when the flower blooms. The leaves on the stem are alternate phyllotaxis and are lanceolate or elliptical lanceolate, and are 12 to 15 cm long.

In the composition for preventing and improving cranial nerve disease, the cranial nerve disease is selected from the group consisting of neurodegenerative diseases, diseases and psychiatric disorders caused by ischemia or reperfusion, and the neurodegenerative diseases are Parkinson's disease, Huntington's disease, Alzheimer's disease, mild Cognitive impairment, senile dementia, amyotrophic lateral sclerosis, Spinocerebellar Atrophy, Tourette's Syndrome, Friedrich's Ataxia, Machado-Joseph's disease ( Machado-Joseph's disease), Lewy Body Dementia, Dystonia, Progressive Supranuclear Palsy and Frontotemporal Dementia may be selected from the group consisting of.

A pharmaceutical according to another embodiment of the present invention may include the composition.

The pharmaceutical or pharmaceutical composition of the present invention may be administered orally or parenterally, and is preferably applied by oral administration. A suitable dosage for the drug of the present invention may be prescribed in various ways depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity of the patient. can A preferred dosage for the pharmaceutical of the present invention is within the range of 0.001-100 mg/kg for adults.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, syrup, or emulsion in oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.

Food according to another embodiment of the present invention may include the composition.

When the composition of the present invention is prepared as food, it includes not only the annual extract as an active ingredient, but also ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, seasonings and Contains flavoring agents. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

The food composition of the present invention includes all types of functional foods, nutritional supplements, health foods, and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the mixed extract of one year bong itself can be prepared and consumed in the form of tea, juice, and drink, or it can be consumed by granulation, encapsulation, and powder. In addition, it can be prepared in the form of a composition by mixing the mixed extract of the present invention with a known active ingredient known to be effective in preventing or improving stress or an active ingredient known to be effective in improving memory loss.

The present invention provides a composition for improving memory and cognitive function.

The present invention provides a composition for preventing and improving cranial nerve diseases including dementia and Alzheimer's.

The present invention provides a composition capable of exhibiting a rapid improvement effect in the early stage with excellent initial activity, and having no problem of side effects due to long-term administration using a plant-derived natural extract.

The present invention provides a food composition that can improve learning ability and concentration.

1 relates to a neuroprotective activity test result of a composition according to an embodiment of the present invention.
Figure 2 relates to the neuroprotective activity test results of the composition according to an embodiment of the present invention.
Figure 3 relates to the experimental results of the Parkinson's disease prevention effect of the composition according to an embodiment of the present invention.
4 is related to the experimental results of the Parkinson's disease prevention effect of the composition according to an embodiment of the present invention.
5 relates to an experiment on the cognitive function and memory improvement effect of the composition according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

[Preparation Example: Preparation and mixing of extract]

1. Preparation of one-year-old extract

Iryeonbong was pulverized to make a powder, and then dried. After hot-water extraction, filtration and vacuum concentration to prepare the Ilnyeonbong extract (E1).

2. Preparation of other extracts

New green extract (E2), milk thistle extract (E3), and mountain chrysanthemum extract (E4) were prepared in the same manner as the above onenyeonbong extract.

3. Preparation of Mixed Extracts

In order to confirm the synergistic effect of mixing each extract, each extract was mixed with the composition shown in [Table 1] below.

T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 E1 100 100 100 100 100 100 100 100 100 100 E2 350 400 450 500 550 450 450 450 450 450 E3 - - - - - 20 40 60 80 100 E4 - - - - - 0.5 One 2 3 4

(Unit: parts by weight)

[Experimental Example 1: Neuroprotective effect test]

SK-N-SH cells, which are human neuroblastoma cells, were seeded at a density of 15,000 cells/well in 96-wells (Nunc, Slangerup, Denmark) and cultured for 24 hours. The cell culture medium was replaced with DMEM containing 1% FBS and further cultured for 2 hours. New Green extract was added to the cultured cells to a concentration of 10, and as a negative control, the same amount of phosphate buffered saline (pH 7.4) was added and incubated for additional 2 hours. _{Thereafter, Aβ 1-42} was added to the culture medium of each group so as to be 20, and incubated for an additional 2 hours. As _{a negative control for Aβ 1-42} treatment, phosphate buffered saline (pH 7.4) was added in the same amount and cultured.

Thereafter, alamarblue (Serotec, Oxford, UK) was treated with 10 μl, incubated for 3 hours, and absorbance was measured at 570 nm using an ELISA reader (Molecular Divices, Sunnycale, CA, USA). Background absorbance (blank count) was a value measured at 600 nm.

In order to confirm the neuroprotective effect of E1 to E4, beta amyloid protein (Aβ) was added to neuroblastoma. The addition of beta-amyloid protein (Aβ) to neuroblastoma caused apoptosis in the form of apoptosis. On the other hand, in the case of E1 and E2, it was possible to confirm cell survival similar to that of the non-treated beta-amyloid protein (Aβ).

On the other hand, in the case of the mixed extract, it was possible to confirm a certain synergistic effect in the range of T2 to T4, and in particular, in the case of T7 to T9, it was possible to confirm a fairly excellent cell survival of about 90% with an additional synergistic effect.

[Experimental Example 2: Parkinson's disease prevention effect test]

The method of Joo et al. (Joo WS et al. , Neuroreport, 9(18), 4123-4126, 1998), an animal model was prepared as follows.

A male Sprague-Dawley white paper weighing 200-250 g was anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (50 mg/kg). Anesthetized animals were perforated into the skull using a stereotaxic surgical instrument (stereotaxic frame, David Kopf, USA), 0.2 mg/ml ascorbic acid was used for the control group (sham group), and dopamine hydroxide (hydroxylated group) was used for the lesioned group. 20 μg/5 μl free base in 0.2 mg/ml ascorbic acid) was injected into the right striatum using a Hamilton syringe (10 μl, 26G needle) at a rate of 1 μl per minute (Paxinos et al., J. Neurosci. Methods 3(2), 129-249, 1980). After injecting the drug, the needle was left there for 5 minutes, the needle was withdrawn at a rate of 1 mm per minute, and the incision was sutured. From 3 days before 6-OHDA administration, the New Green extract prepared in Example 1 was diluted in physiological saline and administered by intraperitoneal injection once daily for 3 days at a dose of 50 mg/kg.

On the other hand, behavioral changes over time in an animal model of Parkinson's disease prepared using hydroxydopamine were subcutaneously injected into the back of the neck on the 14th day after lesion preparation, followed by a unilateral rotational reaction for 60 minutes. was measured.

In this experiment, when dopaminergic neurons die and the concentration of dopamine in the striatum decreases, hypersensitivity of the dopamine receptors in the striatum is induced, and apomorphine acts as an agonist on the dopamine receptors. It uses the principle of rotating in the opposite direction to the injured side (Ungerstedt, Brain Res. 24, 485-493, 2970). Rotational motion was performed using the automated rotometer described in the above paper by Ungerstedt, and each number of rotations was [net turns = contralateral - ipsilateral]. ] was calculated.

Referring to FIG. 3 , there was no significant change in the unilateral net rotation in the normal control group administered with 0.2 mg/ml ascorbic acid to the striatum, but the unilateral rotation in the lesion control group administered only with hydroxydopamine was significantly increased. On the other hand, in the case of E1 and E2, it can be seen that the unilateral net rotation is decreased compared to the lesion control group.

In addition, in the case of the mixed extract, it was confirmed that a certain synergistic effect appeared in the range of T2 to T4 compared to the case of using each of E1 and E2 or simply combining them. In particular, in the case of T7 to T9, as an additional synergistic effect, it was confirmed that the unilateral net rotation was significantly reduced compared to the lesion control group. Through this, it was confirmed that there is an inhibitory effect on Parkinson's disease according to the present invention.

[Experimental Example 3: Cognitive function and memory improvement effect experiment]

Experimental animals were male white paper (Sprague Dawley, 140 to 180 g, Korea Laboratory Animal Center), and they were put in a constant environment (room temperature 25±1℃, relative humidity 60±10%) for a week, and put 4 animals per breeding box. Water was provided without restriction, and at this time, restricted feeding was performed to maintain 80% of body weight. A total of 50 mice were used in this experiment. The test was conducted by acclimatizing to the maze for 5 minutes from 3 days before training.

There are a total of three passages (left, right, and central), and at the entrance to each passage, a “ㅠ”-shaped maze with partitions installed so that the experimenter can control the entrance of animals was prepared.

In the first trial, they were acclimatized to the starting box for 1 minute. The first trial was a 'compulsory selection trial', in which one passage was blocked with a partition, and when an animal entered the other passage, the rear was blocked with a partition. Animals were considered to have entered if their limbs passed through the passage entrance. Animals were allowed to feed in the passage for 60 seconds.

From the next trial, the 'free choice trial' allowed the animal to freely select the direction of the passage (left or right) starting from the starting box. Animals were rewarded with food only when they entered the passageway opposite the passageway they entered in the immediately preceding trial.

The trial interval was configured with a delay of 5 seconds and 20 seconds, and the cut-off time of each trial was 60 seconds. The number of times the animal correctly entered the passageway to which the reinforcement was given and the time it took to enter the passageway were measured. The same procedure was performed for 9 days with 10 trials per day and evaluated.

Meanwhile, E1, E2, and T1 to T10 prepared according to the preparation method of the present invention were prepared in a solution of 100 mg/ml and administered orally. All samples were dissolved in distilled water and administered orally.

The results of the T-maze experiment for the groups administered with E1, E2, and T1 to T10 are shown in [Fig. 5] below. [Fig. 5] shows that the experiment was conducted with the trial interval of 5 seconds, and the performance was gradually improved during the 9-day training period.

On the other hand, it can be seen that the overall synergistic effect is exhibited by the mixture of E1 and E2, and in particular, in the case of T2 to T4, it can be seen that the initial improvement activity is increased and the synergistic effect is overall. In addition, in the case of T7 to T9, it was confirmed that the initial activity was rapidly improved on the 2nd to 4th day.

Therefore, in the case of the composition of the present invention, it is effective in exhibiting the effect of improving cognitive function and memory, and in particular, it is possible to provide functionality excellent in the initial improvement effect. Accordingly, it can be commercialized by applying it to various product groups aimed at improving cognitive function and memory.

Although the preferred embodiment of the present invention has been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention as defined in the following claims are also provided. is within the scope of the

Claims (7)

Containing annual extract
A composition for improving memory and cognitive function. According to claim 1,
which further contains New Green extract
A composition for improving memory and cognitive function. Containing annual extract
A composition for preventing and improving cranial nerve diseases. 4. The method of claim 3,
which further contains New Green extract
A composition for preventing and improving cranial nerve diseases. 5. The method according to claim 3 or 4,
The cranial nerve disease is selected from the group consisting of neurodegenerative diseases, diseases and psychiatric disorders caused by ischemia or reperfusion,
The neurodegenerative diseases include Parkinson's disease, Huntington's disease, Alzheimer's disease, mild cognitive impairment, senile dementia, amyotrophic lateral sclerosis, Spinocerebellar Atrophy, Tourette's Syndrome, Friedrich's Ataxia, Machado-Joseph's disease, Lewy Body Dementia, Dystonia, Progressive Supranuclear Palsy and frontotemporal lobe Dementia (Frontotemporal Dementia) that is selected from the group consisting of
A composition for preventing and improving cranial nerve diseases. A pharmaceutical product comprising the composition according to any one of claims 1 to 5. A food comprising the composition according to any one of claims 1 to 5.

Images